Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

European Research Council grant · Running

AGTC Advancing Gene Transfer Capabilities

Coordinator
Universitair Medisch Centrum Utrecht, Netherlands
Runs
1 November 2025 to 31 October 2030
Status
Running
EU funding
€2.5m
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101200243

What the project is doing

In the project's own words, from its summary on CORDIS.

Innovation: We recently developed a targeted lipid nanopar We recently developed a targeted lipid nanoparticle (tLNP) that can insert a gene directly into the genome of T cells in vivo, with efficiency comparable to viral methods. This innovation creates a unique opportunity to track gene delivery using barcoded synthetic vectors. These barcodes help us understand the key factors needed for effective DNA delivery and the biological consequences of gene transfer.

Background: Gene therapy holds great promise for treating various diseases. Viral vectors are currently the most common method for gene transfer, but they come with limitations like size restrictions on nucleic acids, triggering immune responses, and complicated production processes. Synthetic vectors like LNP have made significant strides, as shown by the success of mRNA COVID-19 vaccines, which demonstrate the efficacy, scalability and cost-effectiveness of LNP.

However, LNP have struggled with efficient gene transfer. Improving this is challenging due to the vast nanomedicine design space and poor correlation between in vitro and in vivo results. Barcoding technology has revolutionized LNP design by allowing higher throughput screening, enabling comprehensive sampling of the design space in living organisms. To apply this to gene transfer, a working prototype is necessary. Our recent success with LNP-mediated gene transfer serves as this foundation for rational optimization of synthetic vectors using DNA-encoded peptide barcodes.

Objectives: The AGTC project will explore three main research lines:1.Nanomedicine Design: Efficiently explore the design space to optimize LNP.2.Targeting: Investigate precision and flexibility of targeting, particularly in T cells.3.T Cell Biology: Link gene transfer to biological activity, focusing on CAR T cells. Outcomes: AGTC will enhance our understanding of what drives effective DNA delivery, paving the way for a new generation of synthetic gene transfer therapies.

Topics

Who is involved

OrganisationCityCountryRole
Universitair Medisch Centrum UtrechtUtrechtNetherlandsCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI